The GALAXY consortium gathers 10 partners from academia and industry in 4 countries. GALAXY brings together partners with unique research competences in clinical hepatology, microbiome, multi-omics, biomarkers and bioinformatics.

Our consortium consists of biologists, medical doctors, bioinformaticians, computer scientists, health economists and SME partners from leading European institutions.


University of Southern Denmark (coordinator)

As an academic center the University of Southern Denmark has a strong tradition for large and advanced clinical studies, with a particular focus on public-private partnerships. The close collaboration between the Clinical Institute at the University and Odense University Hospital provides a tightly integrated environment for the conduct and management of large research projects. The GALAXY project strongly complies with the research- and clinical strategy of the university. The university has seen the largest growth rate in new PhD students, postdocs and professors of all Danish universities within the last years. To accommodate for this growth, the university has built a strong network of supporting functions including accounting, administration and legal department for contracts and IP. The university has also been successful coordinator of several EU grants.


University of Copenhagen

With over 38,000 students and more than 9,000 employees, the University of Copenhagen (UCPH) is one of the largest institutions of research and education in the Nordic countries. Founded more than 530 years ago, the University of Copenhagen is also one of the oldest Universities in Northern Europe. The diversity of academic environments and scientific approaches is the University of Copenhagen`s distinguishing feature and strength.

The University of Copenhagen is an active participant in the Framework Programme, having participated in more than 400 FP7 projects, including 38 projects coordinated by the university. To date, the university is involved in projects and negotiations for 89 Horizon 2020 proposals including 49 individual Marie Curie Fellowships and 7 ERC projects. The University coordinates 4 Horizon 2020 projects.

The Faculty of Health and Medical Sciences is renowned in clinical and pre-clinical medicine and for its research in to cell biology, metabolism and biostatistics. Moreover a range of centers of excellence have grown out of the expertise and strengths of the faculty and contribute greatly to the rich academic environment that attracts researchers from all over the world, including the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR). The section of Metabolic Genetics at CBMR applies a variety of genomic technologies, bioinformatics, and computational statistics. 


Biomedical Research Foundation Academy of Athens

The Biomedical Research Foundation of the Academy of Athens is the most recent addition to the Life Sciences Research establishments in Greece. The goal of BRFAA is to achieve excellence through high quality investigators carrying out cutting-edge research, and the establishment of state-of-the-art research facilities. BRFAA houses more than 400 researchers, focusing on the understanding of basic mechanisms of cardiovascular and nervous systems, cancer, stem cells and metabolic diseases. The founding principle of BRFAA is to host both basic and clinical research thus providing an ideal setting for the emergence of translational activities. BRFAA is one of the few institutions in Europe with such a character and certainly unique in Greece. BRFAA has a deep knowledge of basic research and state-of-the-art facilities. For more than five years, BRFAA has been part of European consortiums for Bio-Banking, and has through this process gained priceless experience and knowledge regarding the collection, handling and storage of samples. The lab has optimized many protocols for preservation of specimens and was first to demonstrate that Laser Capture Microdissection, instead of whole tissue, is crucial to unravel important secrets of mRNA and microRNA deregulation in thyroid cancer. This knowledge is currently being applied to additional tissue types such as liver and expanding to other pathological conditions, including fibrosis.

BRFAA has already achieved an excellent track record in attracting and managing research funding from European and other sources. Since its establishment, BRFAA has participated in a total of 22 EU programs. 

University of Bonn

The Department of Internal Medicine of the University Clinic of Bonn is distinguished for the high number of publications and of impact factor points.  The Laboratory for Liver Fibrosis and Portal Hypertension is headed by Dr. Trebicka. The main areas of experience are experimental and translational liver fibrosis and portal hypertension. The laboratory has expertise in animal models of liver fibrosis and portal hypertension, in mice and rats, as well as in genetically modified animals. Moreover, intracellular pathways involved in fibrogenesis and portal hypertension have been investigated extensively together with the effect of alcohol in various models.

The laboratory is an active participant in a variety of collaborative research centers including the TRR 57 funded by Deutsche Forschungsgemeinschaft with the title: “Organ Fibrosis: From Mechanisms of Injury to Modulation of Disease”. This Laboratory does not only focus on animal models and basic science, but has participated in different multi-centre studies. Examples are the En-Vie study funded by the European Commission 6th Framework Program of Research. Furthermore, the laboratory is part of the Europe-wide CLIF-consortium investigating chronic liver failure, e.g. CANONIC study, INFECIR-2. Many other national and international networks are now in progress and the Laboratory for Portal Hypertension plays an important role in these on-going networks. 


European Molecular Biology Laboratory (EMBL)

EMBL is an international organization employing about 1500 people in five European locations with headquarters in Heidelberg, Germany. Its mandates include the advance of European basic science, particularly in Molecular Biology, the development of advanced technology and instruments, the provision of training and services to the member states as well as technology transfer. The participating group belongs to the Structural and Computational Biology headed by professor P. Bork. The unit has provided both infrastructure and bioinformatics research that has facilitated the development of resources and tools as well as the data analysis of multi-institutional projects.

There is considerable experience in such roles in the context of European projects; the Bork group alone participated, for example, in more than 10 projects of FP6 and FP7, which demonstrates the strong track record in developing large-scale data analysis and integration frameworks. For human gut metagenomic projects, the unit has an established end-to-end sampling to sequence data analysis pipeline in place.

Nordic Bioscience (NB)

Nordic Bioscience is a company focused on biomarker development. Nordic Bioscience has developed over 45 ELISA assays for quantification of biomarkers in serum and urine. Several of these assays have been FDA approved. Nordic Bioscience is focusing on developing and qualification for biomarkers, according to FDAs guidelines use in personalized health care. Nordic Bioscience has a FDA/CAP certified laboratory which allow for analysis of and reporting of human clinical data for regulatory purposes. Nordic Bioscience has commercialized more than 30 ELISAs, and are offering these products and services as biomarkers packages in Buisness-2-Business relationship. In addition, on the open

worldwide market, Nordic Bioscience has commercialized 3 markers on in vitro diagnostic platforms.

Nordic Bioscience is committed to research on the extra cellular matrix and the development of biomarkers related to this pathology. The research group at Nordic has published more than 300 publications in the last 12 years on biomarkers and are world leaders in biomarkers of extra cellular matrix turnover, which is the key feature of many and in particular fibrotic diseases. Nordic bioscience will in this project develop new ELISA assays, measure existing ELISA assays according to FDA standards, and commercialize new products based on results obtained in the program. 


Nordisk Rebalance (NR)

Nordisk Rebalance has developed Profermin, a drug regulating the intestinal environment and thereby creating an impact on the metabolism in and behavior of the intestinal microflora. Founder and director of Nordisk Rebalance A/S Hans Israelsen has worked on business development and documentation of the effect of Profermin, e.g. in studies on inflammatory bowel diseases. The company has extensive experience with management of large research consortiums both with emphasis on scientific matters but also with a strong focus on the commercial outcome. Nordisk Rebalance has shown that the company is capable to develop, document the effect and bring a new product to the market.   


Odense University Hospital (OUH)

The close collaboration between Odense University Hospital and the Institute of Clinical Research, University of Southern Denmark, provides a tightly integrated environment for clinical research. The hospital is referral center for Southern Denmark with a subpopulation of 1.5 million people. Odense University Hospital is also the largest hospital in Denmark with >1200 beds and 10.000 employees. As an academic center there is a strong tradition for large and advanced clinical studies. The clinical studies with recruitment and state-of-the-art clinical investigations in 480 patients and 100 healthy controls are undertaken at the Department of Gastroenterology and Hepatology. The project strongly complies with the research- and clinical strategy of the hospital and the university. Both the department and hospital has a solid research platform and infrastructure for such trials. The department holds the relevant infrastructure to carry out the described studies: state-of-the-art technology, trained key personnel and a large patient flow. Likewise, we benefit from available research support structures: Odense Patient Data Explorative Network (central electronic database, data management), Europe’s most advanced facilities for bio bank tissue storage, the GCP unit (regulatory and legal support for clinical trials to comply with GCP), research service and legal department.


University of Oslo (UO)

The Department of Health management and Health Economics is a department at the Institute for Health and Society at the university of Oslo and represent the largest group of researchers doing work in health economics and economic evaluation in Norway. It consists of more than 30 full time professors and more than 10 PhD candidates. The main task is to teach health economics, management and economic evaluation. The department has a core research group of about 15 individuals who focuses on economic evaluation. This group has long experience in conducting economic evaluations of interventions in the health care sector and has published the results internationally in leading journals. The head of the research group, professor Hans Olav Melberg, has conducted research on economic evaluation in many health areas, but also specifically on the effects of alcohol. He has, moreover, been involved in several large international projects involving the comparison of registry data across from different countries. The core expertise thus combines both economic evaluation in health economics, statistical expertise in handling and combining data from several countries, as well as experience in the specific field of addiction and alcohol research.

Steno Diabetes Centre

The Steno Diabetes Center is an internationally leading tertiary referral centre for the care of patients with diabetes. Research and development go hand in hand with patient care, and both clinical and basic research match high international standards. Steno Diabetes Center is associated with the University of Copenhagen through the university’s hospitals management forum. The current structure of Steno comprises 4 main departments: the clinic (patient care centre) which provides comprehensive care for 6,000 patients with diabetes, the research department, comprising a range of basic and clinical research teams, a new centre for health promotion and preventive medicine and a centre for education and outreach. Department of Systems Medicine and Metabolomics Laboratory at Steno are together an interdisciplinary unit dedicated to the studies of metabolism and related biomarkers in health and disease. The core expertise of the research team covers the areas of computational biology, bioinformatics, metabolomics, and medical systems biology. The team has state-of-the-art facilities in these domains. The analytical infrastructures for metabolomics include four mass spectrometers coupled to various chromatographic systems, fully dedicated to clinical applications.


Norgine A/S

Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2015, Norgine’s total revenue was EUR 320 million and the company employs over 1,000 people.
Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients.  Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.
Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.
For more information, please visit
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit
NORGINE and the sail logo are trademarks of the Norgine group of companies.